MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parker, W. B.
Right arrow Articles by Bennett, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parker, W. B.
Right arrow Articles by Bennett, L. L., Jr.

Vol. 55, Issue 3, 515-520, March 1999

Comparison of the Mechanism of Cytotoxicity of 2-Chloro-9-(2-deoxy-2-fluoro-beta -D-arabinofuranosyl)adenine, 2-Chloro-9-(2-deoxy-2-fluoro-beta -D-ribofuranosyl)adenine, and 2-Chloro-9-(2-deoxy-2,2-difluoro-beta -D-ribofuranosyl)adenine in CEM Cells

William B. Parker, Sue C. Shaddix, Lucy M. Rose, Donna S. Shewach, Larry W. Hertel, John A. Secrist, III, John A. Montgomery, and L. Lee Bennett, Jr.

Southern Research Institute, Birmingham, Alabama (W.B.P., S.C.S., L.M.R., J.A.S., J.A.M., L.L.B.); Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, Michigan (D.S.S.); and Lilly Research Laboratories, Indianapolis, Indiana (L.W.H.)

In an effort to understand biochemical features that are important to the selective antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta -D-arabinofuranosyl)adenine [Cl-F(up-arrow )-dAdo], we evaluated the biochemical pharmacology of three structurally similar compounds that have quite different antitumor activities. Cl-F(up-arrow )-dAdo was 50-fold more potent as an inhibitor of CEM cell growth than were either 2-chloro-9-(2-deoxy-2-fluoro-beta -D-ribofuranosyl)adenine [Cl-F(down-arrow )-dAdo] or 2-chloro-9-(2-deoxy-2,2-difluoro-beta -D-ribofuranosyl)adenine [Cl-diF(up-arrow down-arrow )-dAdo]. The compounds were similar as substrates of deoxycytidine kinase. Similar amounts of their respective triphosphates accumulated in CEM cells, and the rate of disappearance of these metabolites was also similar. Cl-F(up-arrow )-dAdo was 10- to 30-fold more potent in its ability to inhibit the incorporation of cytidine into deoxycytidine nucleotides than either Cl-F(down-arrow )-dAdo or Cl-diF(up-arrow down-arrow )-dAdo, respectively, which indicated that ribonucleotide reductase was differentially inhibited by these three compounds. Thus, the differences in the cytotoxicity of these agents toward CEM cells were not related to quantitative differences in the phosphorylation of these agents to active forms but can mostly be accounted for by differences in the inhibition of ribonucleotide reductase activity. Furthermore, the inhibition of RNA and protein synthesis by Cl-F(down-arrow )-dAdo and Cl-diF(up-arrow down-arrow )-dAdo at concentrations similar to those required for the inhibition of DNA synthesis can help explain the poor antitumor selectivity of these two agents because all cells require RNA and protein synthesis.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
V. Gandhi, W. Plunkett, P. L. Bonate, M. Du, B. Nowak, S. Lerner, and M. J. Keating
Clinical and Pharmacokinetic Study of Clofarabine in Chronic Lymphocytic Leukemia: Strategy for Treatment.
Clin. Cancer Res., July 1, 2006; 12(13): 4011 - 4017.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Faderl, S. Verstovsek, J. Cortes, F. Ravandi, M. Beran, G. Garcia-Manero, A. Ferrajoli, Z. Estrov, S. O'Brien, C. Koller, et al.
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Blood, July 1, 2006; 108(1): 45 - 51.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Jeha, P. S. Gaynon, B. I. Razzouk, J. Franklin, R. Kadota, V. Shen, L. Luchtman-Jones, M. Rytting, L. R. Bomgaars, S. Rheingold, et al.
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
J. Clin. Oncol., April 20, 2006; 24(12): 1917 - 1923.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. M. King, V. L. Damaraju, M. F. Vickers, S. Y. Yao, T. Lang, T. E. Tackaberry, D. A. Mowles, A. M. L. Ng, J. D. Young, and C. E. Cass
A Comparison of the Transportability, and Its Role in Cytotoxicity, of Clofarabine, Cladribine, and Fludarabine by Recombinant Human Nucleoside Transporters Produced in Three Model Expression Systems
Mol. Pharmacol., January 1, 2006; 69(1): 346 - 353.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
Z. Bebok, J. F. Collawn, J. Wakefield, W. Parker, Y. Li, K. Varga, E. J. Sorscher, and J. P. Clancy
Failure of cAMP agonists to activate rescued {Delta}F508 CFTR in CFBE41o- airway epithelial monolayers
J. Physiol., December 1, 2005; 569(2): 601 - 615.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Faderl, V. Gandhi, S. O'Brien, P. Bonate, J. Cortes, E. Estey, M. Beran, W. Wierda, G. Garcia-Manero, A. Ferrajoli, et al.
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
Blood, February 1, 2005; 105(3): 940 - 947.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Jeha, V. Gandhi, K. W. Chan, L. McDonald, I. Ramirez, R. Madden, M. Rytting, M. Brandt, M. Keating, W. Plunkett, et al.
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
Blood, February 1, 2004; 103(3): 784 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Gandhi, H. Kantarjian, S. Faderl, P. Bonate, M. Du, M. Ayres, M. B. Rios, M. J. Keating, and W. Plunkett
Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias
Clin. Cancer Res., December 15, 2003; 9(17): 6335 - 6342.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kantarjian, V. Gandhi, J. Cortes, S. Verstovsek, M. Du, G. Garcia-Manero, F. Giles, S. Faderl, S. O'Brien, S. Jeha, et al.
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
Blood, October 1, 2003; 102(7): 2379 - 2386.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. M. Kantarjian, V. Gandhi, P. Kozuch, S. Faderl, F. Giles, J. Cortes, S. O'Brien, N. Ibrahim, F. Khuri, M. Du, et al.
Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers
J. Clin. Oncol., March 15, 2003; 21(6): 1167 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Someya, S. C. Shaddix, K. N. Tiwari, J. A. Secrist III, and W. B. Parker
Phosphorylation of 4'-thio-beta -D-Arabinofuranosylcytosine and Its Analogs by Human Deoxycytidine Kinase
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1314 - 1322.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey
Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia
J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Cardoen, E. Van Den Neste, C. Smal, J.-F. Rosier, A. Delacauw, A. Ferrant, G. Van den Berghe, and F. Bontemps
Resistance to 2-Chloro-2'-deoxyadenosine of the Human B-cell Leukemia Cell Line EHEB
Clin. Cancer Res., November 1, 2001; 7(11): 3559 - 3566.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics